What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
出版年份 2021 全文链接
标题
What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
作者
关键词
-
出版物
Cancer Medicine
Volume 11, Issue 2, Pages 332-339
出版商
Wiley
发表日期
2021-12-18
DOI
10.1002/cam4.4449
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis
- (2020) Hao Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial
- (2019) Serena Di Cosimo et al. CLINICAL CANCER RESEARCH
- The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
- (2019) Serena Di Cosimo et al. EUROPEAN JOURNAL OF CANCER
- MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
- (2018) Alessandra Cataldo et al. Oncotarget
- HER2-positive breast cancer is lost in translation: time for patient-centered research
- (2017) Isabelle Gingras et al. Nature Reviews Clinical Oncology
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developing miRNA signatures: a multivariate prospective
- (2016) Paolo Verderio et al. BRITISH JOURNAL OF CANCER
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
- (2015) Leticia De Mattos-Arruda et al. Oncotarget
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
- (2013) Katherine L. Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
- (2011) Hajime Uno et al. STATISTICS IN MEDICINE
- A novel and universal method for microRNA RT-qPCR data normalization
- (2009) Pieter Mestdagh et al. GENOME BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now